Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 2Short Bowel Syndrome 1Esophageal Squamous Cell Carcinoma 1Diarrhea 1Colorectal Neoplasms 1Colonic Neoplasms 1Colitis, Ulcerative 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 51Capecitabine 42Irinotecan 29Bevacizumab 21Radiotherapy 17Cetuximab 12Folfox protocol 11Chemoradiotherapy 11Neoadjuvant Therapy 10Chemotherapy, Adjuvant 9Surgical Procedures, Operative 6Drug Therapy 6XELOX 5Panitumumab 4Laparoscopy 4FOLFOXIRI protocol 4Transanal Endoscopic Microsurgery 3Radiation 3Octreotide 3IFL protocol 3Floxuridine 3Diathermy 3Celecoxib 3vatalanib 2spartalizumab 2Trinitrotoluene 2Tegafur 2Semaxinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Rectal Neoplasms × Loperamide × Clear all
NCT00003057 2023-06-18

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
500 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

NCT02266849 2016-10-11

Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study

Odense University Hospital

Phase 3 Terminated
12 enrolled
Gastrointestinal

Colitis, Ulcerative, Rectal Neoplasms, Short Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡